Cancer
Evidence-Based Colorectal Cancer Prevention: What the Guidelines Actually Support
USPSTF, WHO, and NCI guidance converge on screening from age 45, high fiber intake, limiting processed and red meat, regular exercise, weight management, low alcohol, and not smoking — with vitamin D and calcium supplementation showing weaker and mixed evidence.
Dostarlimab in dMMR Rectal Cancer: 100% Complete Response at Memorial Sloan Kettering
A neoadjuvant PD-1 inhibitor trial at Memorial Sloan Kettering produced complete responses in every mismatch-repair-deficient rectal cancer patient treated, sustained across five years — but the result applies only to the 5-10% of rectal cancers with this genetic subtype.
Nous-209: Off-the-Shelf Neoantigen Vaccine for Lynch Syndrome Cancer Prevention
Nous-209 is an off-the-shelf cancer vaccine that uses gorilla adenovirus and modified vaccinia Ankara vectors to display ~200 shared neoantigens, generating immune responses in 100% of Lynch syndrome carriers in a 2026 Phase 1b/2 trial.
ELI-002 (AMPLIFY-201): KRAS-Targeted Amphiphile Vaccine for Minimal Residual Disease
ELI-002 is an amphiphile-based therapeutic cancer vaccine targeting mutant KRAS proteins after surgery, with a Phase 1 trial showing mKRAS-specific T-cell responses in 84% of patients and median relapse-free survival far exceeding historical controls.